443794-40-9

Usage

Uses

Used in Pharmaceutical Industry:
9H-Fluorene-2,7-dicarboxamide, 9-oxo-N,N'-bis(3-phenylpropyl)is used as a PARG inhibitor for amelioration of ischemic brain damage in rats. Its ability to reduce brain infarct volumes and modulate the inflammatory response makes it a promising candidate for the treatment of cerebral ischemia and other related conditions.
Used in Oncology Research:
GPI-16552 is used as a research tool in oncology to study the synergistic effects of PARG inhibition and temozolomide in decreasing melanoma cell invasion and metastatic spreading. This application aids in understanding the potential therapeutic benefits of combining these two agents in the treatment of melanoma and possibly other cancer types.

References

1) Zhang?et al. (2002),?PARP and PARG as novel therapeutic targets; Drugs Future,?27?371 2) Lu?et al. (2003),?Post-treatment with a novel PARG inhibitor reduces infarct in cerebral ischemia in the rat; Brain Res.,978?99 3) Cuzzocrea?et al. (2005),?PARG activity mediates intestinal injury induced by splanchnic artery occlusion and reperfusion; FASEB J.,?19?558 4) Cuzzocrea?et al. (2006),?Poly(ADP-ribose) glycohydrolase activity mediates post-traumatic inflammatory reaction after experimental spinal cord trauma; J. Pharmacol. Exp. Ther.,?319?127 5) Tentori?et al. (2005),?Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide; Eur. J. Cancer,?41?2948